Enric Alvarez Mart A-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4875728/publications.pdf

Version: 2024-02-01

43 papers 2,185 citations

201658 27 h-index 254170 43 g-index

43 all docs 43 docs citations

43 times ranked

2834 citing authors

#	Article	IF	CITATIONS
1	Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, The, 1997, 349, 1594-1597.	13.7	304
2	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 2012, 15, 589-600.	2.1	181
3	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: A comparison among first episode, remitted recurrent and chronic patients. Journal of Psychiatric Research, 2011, 45, 427-434.	3.1	115
4	Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychological Medicine, 2014, 44, 1171-1182.	4.5	110
5	Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2015, 161, 261-268.	2.0	106
6	Decreased plasma serotonin in melancholic patients: A study with clomipramine. Biological Psychiatry, 1987, 22, 1429-1438.	1.3	81
7	A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. Journal of Affective Disorders, 2010, 120, 221-225.	4.1	80
8	Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophrenia Research, 2009, 115, 58-66.	2.0	75
9	SPECT mapping of cerebral activity changes induced by repetitive transcranial magnetic stimulation in depressed patients. A pilot study. Psychiatry Research - Neuroimaging, 2001, 106, 151-160.	1.8	70
10	Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. Journal of Affective Disorders, 1992, 25, 243-249.	4.1	69
11	Augmentation of Fluoxetine's Antidepressant Action by Pindolol: Analysis of Clinical, Pharmacokinetic, and Methodologic Factors. Journal of Clinical Psychopharmacology, 2001, 21, 36-45.	1.4	60
12	Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry, 2006, $21, 11-20$.	0.2	52
13	Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatric Genetics, 2006, 16, 25-29.	1.1	51
14	Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophrenia Research, 2009, 108, 214-222.	2.0	50
15	Enhanced binding of [³ H] (â€) adrenaline to platelets of depressed patients with melancholia: Effect of longâ€term clomipramine treatment. Acta Psychiatrica Scandinavica, 1987, 75, 150-157.	4.5	46
16	Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analyses of schizophrenia. European Psychiatry, 2005, 20, 550-553.	0.2	46
17	Regulation of Platelet α2A-Adrenoceptors, Gi Proteins and Receptor Kinases in Major Depression: Effects of Mirtazapine Treatment. Neuropsychopharmacology, 2004, 29, 580-588.	5.4	44
18	Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology, 1989, 99, 328-332.	3.1	43

#	Article	IF	Citations
19	Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology, 2006, 189, 145-153.	3.1	43
20	Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug and Alcohol Dependence, 2007, 89, 190-194.	3.2	43
21	Altered amplitude of low frequency fluctuations in schizophrenia patients with persistent auditory verbal hallucinations. Schizophrenia Research, 2017, 189, 97-103.	2.0	43
22	Preclinical and clinical characterization of the selective 5â€HT _{1A} receptor antagonist DUâ€125530 for antidepressant treatment. British Journal of Pharmacology, 2012, 167, 1021-1034.	5.4	40
23	Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neurolmage, 2006, 29, 662-666.	4.2	38
24	Injectable Atypical Antipsychotics for Agitation in Borderline Personality Disorder. Pharmacopsychiatry, 2006, 39, 117-118.	3.3	31
25	Relationship Between Blood Serotonergic Variables, Melancholic Traits, and Response to Antidepressant Treatments. Journal of Clinical Psychopharmacology, 1998, 18, 222-230.	1.4	31
26	Predicting outcome of lithium added to antidepressants in resistant depression. Journal of Affective Disorders, 1997, 42, 179-186.	4.1	30
27	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Research, 2012, 200, 693-701.	3.3	29
28	Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls. Journal of Affective Disorders, 1993, 29, 227-234.	4.1	28
29	Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: Antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. European Neuropsychopharmacology, 2010, 20, 721-730.	0.7	28
30	Pindolol augmentation enhances response outcomes in first depressive episodes. European Neuropsychopharmacology, 2009, 19, 516-519.	0.7	24
31	Urinary phenylacetic acid excretion in depressive patients. Acta Psychiatrica Scandinavica, 1988, 78, 208-210.	4.5	21
32	Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression: An exploratory study. Psychiatry Research, 2015, 225, 341-346.	3.3	21
33	Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression. Journal of Affective Disorders, 2015, 173, 159-162.	4.1	20
34	Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 91-96.	4.8	19
35	Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Research - Neuroimaging, 2006, 148, 175-183.	1.8	19
36	Depressive Relapse After Initial Response to Subcallosal Cingulate Gyrus-Deep Brain Stimulation in a Patient with a Treatment-Resistant Depression: Electroconvulsive Therapy as a Feasible Strategy. Biological Psychiatry, 2009, 66, e11-e12.	1.3	19

#	Article	IF	CITATIONS
37	Regional differences in treatment response and three year course of schizophrenia across the world. Journal of Psychiatric Research, 2012, 46, 856-864.	3.1	16
38	The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. Journal of Affective Disorders, 2014, 169, 189-196.	4.1	13
39	Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 767-770.	4.8	12
40	Clinical and serotonergic predictors of nonâ€affective acute remitting psychosis in patients with a firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2009, 119, 71-77.	4.5	10
41	Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review. Perspectives in Psychiatric Care, 2012, 48, 198-207.	1.9	8
42	A psychometric analysis of the Clinically Useful Depression Outcome Scale (CUDOS) in Spanish patients. Journal of Affective Disorders, 2013, 151, 920-923.	4.1	8
43	Letter to the Editor: Deep brain stimulation for schizophrenia. Journal of Neurosurgery, 2016, 125, 229-230.	1.6	8